NAMD submitted comments to the Health Care Payment Learning Action Network on its draft white paper on clinical episode payment for maternity care. The comments highlight state Medicaid considerations when designing a clinical episode payment model for maternity care. Read full letter.
On May 18, NAMD submitted comments to the Health Resources and Services Administration (HRSA) in response to reopened provisions of a proposed rule on the 340B drug discount program. NAMD called for HRSA to maintain its initially proposed “penny pricing” method for 340B drugs, for HRSA to align the 340B ceiling price for new drugs […]
NAMD sent a letter to sponsors of the legislation, “Advancing Care for Exceptional for Kids.” The letter addresses the bill’s underlying structure and implementation issues as well as other opportunities to enhance access to care coordination and high quality services for children with complex medical needs. Read full letter.
NAMD sent a letter to House of Representatives leadership on the need to address the privacy laws governing substance use disorder information as part of opioid legislation under consideration in the House. The letter underscores the need to amend the privacy laws of 42 CFR Part 2 to fully address the opioid crisis, and ensure […]
On April 29, NAMD sent a letter to leadership of the Senate Finance Committee and the Senate Health, Education, Labor, and Pensions Committee addressing Senators’ efforts to improve the nation’s behavioral health system. In particular, NAMD praised the Committees for their consideration of lifting restrictions on federal Medicaid payments for services provided in Institutions for […]
This memo aims to support Medicaid Directors in reviewing CMS’s final rule implementing mental health parity requirements in Medicaid under the Mental Health Parity and Addiction Equity Act of 2008. The document explores state Medicaid program and MCO roles and responsibilities under the rule, as well as the general parity requirements. It also highlights key […]
NAMD staff prepared a memo for Directors outlining key federal regulatory and legislative priorities for the remainder of the year. It provides a snapshot of major priorities for HHS, including completion of the final Medicaid managed care rule, systems work, and value-based purchasing. It also provides an assessment of legislation which is likely to impact […]
NAMD prepared a memo providing a summary of the Center for Medicare and Medicaid Innovation (CMMI)’s recently-announced Comprehensive Primary Care Plus (CPC+) care model. The memo summarizes the model’s goals, its main features, key components for payers to consider in applying to the model, and potential pros and cons for state participation. Read the full […]
NAMD submitted comments to the Substance Abuse and Mental Health Services Administration (SAMHSA) on a proposed rule addressing the confidentiality of substance use disorder information (42 CFR Part 2). In the letter, NAMD requests SAMHSA revise the proposed rule to better support care coordination and information exchange to ensure patient safety and positive outcomes. Read […]
NAMD submitted comments to CMS on the final Medicaid covered outpatient drug rule. In the comments, NAMD calls attention to implementation timeline challenges posed by the rule and provides a suggested approach for handling line extension drugs. Read full letter.